Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.

Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G, Wolchok JD, Houghton AN.

J Exp Med. 2009 Apr 13;206(4):849-66. doi: 10.1084/jem.20081382. Epub 2009 Mar 30.

2.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
3.

Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.

Jorritsma A, Bins AD, Schumacher TN, Haanen JB.

Cancer Res. 2008 Apr 1;68(7):2455-62. doi: 10.1158/0008-5472.CAN-07-5254.

4.

Regulation of secondary antigen-specific CD8(+) T-cell responses by natural killer T cells.

Hong C, Lee H, Park YK, Shin J, Jung S, Kim H, Hong S, Park SH.

Cancer Res. 2009 May 15;69(10):4301-8. doi: 10.1158/0008-5472.CAN-08-1721. Epub 2009 Apr 28.

5.

[New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].

Ma J, Wang YL, Hu HM, Fox BA, Si LS.

Zhonghua Zhong Liu Za Zhi. 2005 Aug;27(8):452-6. Chinese.

PMID:
16188138
6.

In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.

Kalat M, Küpcü Z, Schüller S, Zalusky D, Zehetner M, Paster W, Schweighoffer T.

Cancer Res. 2002 Oct 1;62(19):5489-94.

7.

Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.

Sivinski CL, Kohlgraf KG, VanLith ML, Morikane K, Tempero RM, Hollingsworth MA.

Cancer Immunol Immunother. 2002 Aug;51(6):327-40. Epub 2002 May 4.

PMID:
12111121
8.

[Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].

Benchetrit F, Gazagne A, Adotevi O, Haicheur N, Godard B, Badoual C, Fridman WH, Tartour E.

Bull Cancer. 2003 Aug-Sep;90(8-9):677-85. Review. French.

9.

In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.

Speiser DE, Liénard D, Pittet MJ, Batard P, Rimoldi D, Guillaume P, Cerottini JC, Romero P.

Eur J Immunol. 2002 Mar;32(3):731-41.

10.

Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.

Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P.

Cancer Res. 2000 Aug 15;60(16):4499-506.

11.

Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.

Snook AE, Magee MS, Schulz S, Waldman SA.

Eur J Immunol. 2014 Jul;44(7):1956-66. doi: 10.1002/eji.201444539. Epub 2014 May 21.

12.

Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A.

Cancer Res. 2003 May 15;63(10):2535-45.

13.

The immune response to melanoma is limited by thymic selection of self-antigens.

Träger U, Sierro S, Djordjevic G, Bouzo B, Khandwala S, Meloni A, Mortensen M, Simon AK.

PLoS One. 2012;7(4):e35005. doi: 10.1371/journal.pone.0035005. Epub 2012 Apr 10.

15.
16.

Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.

Altvater B, Pscherer S, Landmeier S, Kailayangiri S, Savoldo B, Juergens H, Rossig C.

Cancer Immunol Immunother. 2012 Mar;61(3):385-96. doi: 10.1007/s00262-011-1111-6. Epub 2011 Sep 18.

PMID:
21928126
17.

Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.

Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, Ames E, Bruhn KW, Craft N, Wiltrout RH, Longo DL, Lanier LL, Blazar BR, Redelman D, Murphy WJ.

Blood. 2012 Mar 29;119(13):3073-83. doi: 10.1182/blood-2011-07-369736. Epub 2012 Jan 17.

18.

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C.

Cancer Res. 2005 Mar 1;65(5):1761-9.

19.

Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.

Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P, Speiser DE, Rufer N.

J Immunol. 2009 Oct 15;183(8):5397-406. doi: 10.4049/jimmunol.0901460. Epub 2009 Sep 28.

20.

Supplemental Content

Support Center